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and to alter the substrate specificity 
of the mutated EZH2 in diffuse large 
B-cell lymphoma and follicular lym-
phoma. Importantly, lymphomas har-
boring these mutations in the EZH2 
gene can be successfully targeted by 
a potent, highly selective, S-adenosyl-
methionine-competitive, small-molecu-
lar inhibitor of EZH2 methyltransferase 
activity, that is, GSK126, in in vitro and 
in vivo models.4
Although recent integrative 
genomic analyses identified recurrent 
mutations of SCLC, such as the cAMP-
response element binding protein 
(CREB) binding protein (CREBBP), 
E1A binding protein p300 (EP300), 
and mixed-lineage leukemia (MLL) 
genes that encode histone modifiers, as 
well as the inactivation of tumor pro-
tein p53 (TP53) and retinoblastoma 
1 (RB1), mutations of the EZH2 gene 
have not yet been identified. In addition 
to the report by Peifer et al.,5 our analy-
sis of 35 patients diagnosed with SCLC 
failed to identify mutations of the EZH2 
gene in the SET domain.
In conclusion, we feel that further 
studies should be focused on the identi-
fication of mutations of the EZH2 gene, 
and if any are found, it should be clarified 
which of the overexpressed or mutated 
EZH2 genes most intensely promote 
SCLC tumorigenesis. Furthermore, it 
should be  elucidated which of these 
alterations can be successfully targeted 
for patients with SCLC. 
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To the Editor:
I read the article by Hubaux et al.1 
entitled “EZH2 promotes E2F-driven 
SCLC tumorigenesis through modula-
tion of apoptosis and cell-cycle regula-
tion” with much interest. In their study, 
the authors indicated that the stable 
down-regulation of the enhancer of 
zeste homolog 2 (EZH2) gene by short 
hairpin RNA modulates apoptosis and 
the cell cycle, which results in a reduc-
tion of the viability of small-cell lung 
cancer (SCLC) cell lines, and concluded 
that EZH2 can be a potential therapeu-
tic target for SCLC. Indeed, EZH2 is 
known to be targeted by Polycomb 
repressor complex 2 inhibitors, that is, 
S-adenosyl-homocysteine hydrolase 
inhibitor 3-deazaneplanocin A.2
Several reports suggested that 
EZH2 is overexpressed at the protein 
level in various types of solid tumors, 
including lung cancer, and its overex-
pression correlates with a poor prog-
nosis in patients with resected lung 
cancer.3 Additionally, somatic muta-
tions within two residues in the cata-
lytic SET domain of the EZH2 gene 
(Y641 and A677) were identified to 
have increased H3K27 trimethylation 
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In Response:
We thank Dr. Toyokawa and col-
leagues for their interest and for their 
thoughtful comments regarding our 
article demonstrating the importance 
of EZH2 in small-cell lung cancer 
(SCLC) tumorigenesis.1 Their letter to 
the Editor reiterates that EZH2 overex-
pression occurs in several cancer types 
and that it correlates with poor progno-
sis in lung cancer patients. Importantly, 
they also discuss the role of muta-
tions in the catalytic SET domain as 
a mechanism of EZH2 activation in 
lymphomas, for which potent inhibi-
tors have been shown to have thera-
peutic efficacy in vivo. They reaffirm 
EZH2 as an attractive therapeutic target 
given the prominence of its activation in 
SCLC. However, EZH2 mutations were 
not detected in a recent SCLC study 
(N = 29), nor in Toyokawa’s own cohort 
of SCLCs (N=35), raising the question 
of how EZH2 becomes aberrantly acti-
vated in SCLC.2
We further investigated pub-
lic data to detect EZH2 SET domain 
mutations in SCLC. None were iden-
tified in the NCI-H209 SCLC cell 
line sequence, in 42 SCLC exome 
sequences,3 or in 121 SCLCs with 
EZH2 mutation status in the COSMIC 
database. It is apparent that unlike 
other cancer types, mutations are not 
a common mechanism of EZH2 acti-
vation in SCLC. Furthermore, analy-
sis of data from two recent studies 
on SCLC tumors and cell lines from 
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the Sanger Institute’s Cancer Genome 
Project revealed that EZH2 was not a 
target of DNA amplification, which is 
consistent with our recent findings,4 
ruling out copy number alteration as 
a mechanism of EZH2 activation.2,3 
MicroRNA down-regulation is another 
possible mechanism of EZH2 up-reg-
ulation. EZH2 is a known target of 
miR-101, which is downregulated in 
cancer, although we have shown that 
miR-101 DNA copy loss is not promi-
nent in SCLC.5 We assessed copy sta-
tus of other EZH2-targeting miRNA 
using Sanger’s data on 53 SCLC lines. 
miR-124, miR-138, miR-26a, and 
miR-98 exhibited frequent single copy 
loss (38%–81% of samples), however, 
none of these miRNA were located 
within significant chromosomal 
regions of loss in recent tumor pro-
filing studies, and expression should 
be assessed to accurately determine 
miRNA status.2,3
Recently, we investigated the 
E2F/Rb pathway upstream of EZH2 
and discovered that disruption of this 
pathway is a prominent mechanism of 
EZH2 activation in SCLC.4 We identi-
fied copy loss of RB1 or gains of E2F1, 
E2F2, or E2F3 in 96% of the SCLCs 
we investigated. EZH2 is an estab-
lished transcriptional target of this 
pathway, and concordantly, we found 
that pathway disruption was strongly 
correlated with EZH2 expression. 
Furthermore, we showed that E2F 
manipulation caused changes in EZH2 
protein expression, demonstrating 
the consequence of E2F/Rb pathway 
disruption on EZH2 in SCLC. These 
results suggest that genomic disrup-
tion of upstream regulators is a promi-
nent mechanism of EZH2 activation in 
SCLC.4
Regardless of the EZH2 activa-
tion mechanism, based on the facts that 
(1) EZH2 overexpression is nearly uni-
versal in SCLC, (2) EZH2 expression 
is scarcely detectable in nonmalignant 
tissues throughout the body,4 and (3) 
EZH2 inhibitors are currently avail-
able, we agree with Toyokawa et al. 
and strongly believe that EZH2 is an 
extremely promising therapeutic target 
for this very aggressive cancer. 
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